OncoMatch/Clinical Trials/NCT05525338
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Is NCT05525338 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Alectinib for drug monitoring.
Treatment: Alectinib — The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). The RCT will compare the use of Therapeutic Drug Monitoring (TDM) and dose increases if alectinib 35 ng/Ml (arm A) with standard of care (arm B).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: ALK rearrangement
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–4(Completely disabled)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify